This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A research study conducted by Moderna is testing an investigational vaccine that may protect children who are between the ages of 6 months to < 12 years from getting sick if they come into contact with SARS-COV-2, which causes COVID-19; also known as coronavirus.
Trial ID: NCT04796896
Often vaccines for viruses are made from a weakened or inactive (not live) virus, but the mRNA-1273 study vaccine is different. It is made from an instructional molecule called mRNA that tells your cells how to make protein. In this case, the protein is a small part of the virus that is thought to help the body’s immune system protect itself if you ever come in contact with the coronavirus.
The primary purpose of the KidCOVE Study is to test the safety and effectiveness of the study vaccine, called mRNA-1273, that may protect children between the ages of 6 months to < 12 years from getting sick if they come into contact with SARS-CoV-2, which causes COVID-19. Moderna will be recruiting multiple age groups from 6 months to < 12 years and staggering the recruitment of each group. The goal of this study is to evaluate the safety and effectiveness of different dose amounts and regimens, including a three-dose regimen in children 6 to < 12 years. Please be aware that there may be a delay in hearing from a study site, or the site near you may no longer be recruiting in a specific age group.
Participation in the KidCOVE Study lasts up to 17 months and includes phone calls, telemedicine visits, and up to eight visits to the study site.
The study doctor and medical staff will talk to participants and their caregivers about additional medical support that they will receive if they experience COVID-19 symptoms at any time while in this clinical trial. Insurance is not needed to join this clinical trial, and compensation for your time will be available.
You will need to bring your child to one of the study clinics taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin: